73P - Utilization rates of stereotactic body radiation therapy for the treatment of stage I NSCLC in three European countries
Authors
- R. Damhuis (Utrecht, Netherlands)
- S. Senan (Amsterdam, Netherlands)
- A. Khakwani (Nottingham, United Kingdom)
- S. Harden (Cambridge, United Kingdom)
- A. Helland (Oslo, Norway)
- T. Strand (Oslo, Norway)
Speakers
- R. Damhuis (Utrecht, Netherlands)
31P - Do two lungs form an integrated immune system? Learning from BALF examination in lung cancer
Authors
- J. Domagala-Kulawik (Warsaw, Poland)
- T. Skirecki (Warsaw, Poland)
- D. Dziedzic (Warsaw, Poland)
- M. Polubiec-Kownacka (Warsaw, Poland)
- T. Kryczka (Warsaw, Poland)
- I. Kwiecien (Warsaw, Poland)
Speakers
- J. Domagala-Kulawik (Warsaw, Poland)
36P - Can a BALF profile distinguish hot vs cold lung tumors?
Authors
- J. Domagala-Kulawik (Warsaw, Poland)
- D. Dziedzic (Warsaw, Poland)
- M. Polubiec-Kownacka (Warsaw, Poland)
- T. Kryczka (Warsaw, Poland)
- I. Kwiecien (Warsaw, Poland)
Speakers
- J. Domagala-Kulawik (Warsaw, Poland)
8P - Role of chemokines in resectable non-small cell lung cancer (NSCLC)
Authors
- M. Drosslerová (Prague, Czech Republic)
- M. Šterclová (Prague, Czech Republic)
- M. Vašáková (Prague, Czech Republic)
- A. Tašková (Prague, Czech Republic)
- V. Hytych (Prague, Czech Republic)
- P. Horažďovský (Prague, Czech Republic)
- E. Richterová (Prague, Czech Republic)
- M. Smětáková (Prague, Czech Republic)
- L. Havel (Prague, Czech Republic)
Speakers
- M. Drosslerová (Prague, Czech Republic)
129P - Anlotinib can overcome acquired resistance to EGFR-TKIs via FGFR1 signaling in non-small cell lung cancer
Authors
- Z. Lian (Suzhou, China)
- W. Du (Suzhou, China)
- J. Zhu (Suzhou, China)
- Y. Zeng (Suzhou, China)
- L. Zeyi (Suzhou, China)
- J. Huang (Suzhou, China)
Speakers
- Z. Lian (Suzhou, China)
22P - Paclitaxel/ carboplatin/ bevacizumab in non-small cell lung cancer patients induces peripheral effector CD8 T cell proliferation that could be prone for treatment with checkpoint inhibitors
Authors
- D. Dumoulin (Barendrecht, Netherlands)
- P. De Goeje (Rotterdam, Netherlands)
- M. Poncin (Rotterdam, Netherlands)
- K. Bezemer (Rotterdam, Netherlands)
- H. Groen (Groningen, Netherlands)
- E. Smit (Amsterdam, Netherlands)
- A. Dingemans (Maastricht, Netherlands)
- A. Kunert (Rotterdam, Netherlands)
- R. Hendriks (Rotterdam, Netherlands)
- J. Aerts (Rotterdam, Noord Brabant, Netherlands)
Speakers
- D. Dumoulin (Barendrecht, Netherlands)
154P - Renal toxicity from platinum/pemetrexed and pembrolizumab in the era of combination therapy
Authors
- D. Dumoulin (Barendrecht, Netherlands)
- S. Visser (Breda, Netherlands)
- R. Cornelissen (Rotterdam, Netherlands)
- J. Aerts (Rotterdam, Noord Brabant, Netherlands)
Speakers
- D. Dumoulin (Barendrecht, Netherlands)
47P - Treatment (Tx) patterns and overall survival (OS) in patients (pts) with NSCLC in Sweden: A SCAN-LEAF study analysis from the I-O Optimise initiative
Authors
- S. Ekman (Stockholm, Sweden)
- J. Sørensen (Copenhagen, Denmark)
- O. Brustugun (Oslo, Norway)
- P. Horvat (London, United Kingdom)
- D. Patel (London, United Kingdom)
- M. Rosenlund (Stockholm, Sweden)
- A. Mette Kejs (Copenhagen, Denmark)
- A. Juarez-Garcia (Uxbridge, United Kingdom)
- M. Daumont (Braine-L'Alleud, Belgium)
- L. Lacoin (Ladeuze, Belgium)
- J. Penrod (Princeton, NJ, United States of America)
- J. O'Donnell (Princeton, NJ, United States of America)
- M. Planck (Lund, Sweden)
Speakers
- S. Ekman (Stockholm, Sweden)
3P - Notable variation of molecular testing in metastatic lung cancer in the Netherlands
Authors
- C. Epskamp-Kuijpers (Utrecht, Netherlands)
- M. Van den Heuvel (Nijmegen, Netherlands)
- L. Overbeek (Houten, Netherlands)
- A. Van Lindert (Utrecht, Netherlands)
- R. Damhuis (Utrecht, Netherlands)
- S. Willems (Utrecht, Netherlands)
Speakers
- C. Epskamp-Kuijpers (Utrecht, Netherlands)
179P - Treatment (tx) characteristics of patients (pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC) receiving atezolizumab (atezo) monotherapy in US clinical practice
Authors
- M. Frueh (St. Gallen, Switzerland)
- O. Rahma (Boston, MA, United States of America)
- R. Pachynski (St. Louis, MO, United States of America)
- J. Mazieres (Toulouse, France)
- J. Goldschmidt Jr. (Blacksburg, VA, United States of America)
- T. Ton (South San Francisco, CA, United States of America)
- S. Mhatre (South San Francisco, CA, United States of America)
- C. Chuo (South San Francisco, CA, United States of America)
- J. Martinalbo (Basel, Switzerland)
- J. Davies (Welwyn Garden City, United Kingdom)
- R. Juergens (Hamilton, ON, Canada)
Speakers
- M. Frueh (St. Gallen, Switzerland)
150P - Characterization of patients with metastatic non-small cell lung cancer obtaining long term benefit from immunotherapy
Authors
- G. Galli (Milan, Italy)
- C. Proto (Milano, Italy)
- D. Signorelli (Milan, Italy)
- M. Imbimbo (Milan, Italy)
- R. Ferrara (Milano, Italy)
- A. Prelaj (Milano, Italy)
- A. De Toma (Milano, Italy)
- G. Randon (Milano, Italy)
- B. Trevisan (Milano, Italy)
- M. Ganzinelli (Milano, Italy)
- N. Zilembo (Milano, Italy)
- M. Garassino (Milan, Italy)
- G. Lo Russo (Milano, Italy)
Speakers
- G. Galli (Milan, Italy)
188TiP - Metformin +/- cyclic fasting mimicking diet in combination with platinum-pemetrexed chemotherapy for advanced LKB1 inactive lung adenocarcinoma: The FAME trial
Authors
- G. Galli (Milan, Italy)
- D. Signorelli (Milan, Italy)
- C. Vernieri (Milan, Italy)
- M. Ganzinelli (Milano, Italy)
- M. Moro (Milan, Italy)
- A. Fabbri (Milan, Italy)
- E. Tamborini (Milano, Italy)
- M. Marabese (Milan, Italy)
- E. Caiola (Milan, Italy)
- M. Broggini (Milan, Italy)
- L. Hollander (Milan, Italy)
- R. Gallucci (Milan, Italy)
- C. Gavazzi (Milan, Italy)
- A. Rizzo (Milano, Italy)
- P. Corsetto (Milano, Italy)
- G. Pruneri (Milan, Italy)
- F. De Braud (Milan, Italy)
- G. Sozzi (Milan, Italy)
- V. Torri (No City Provided, Namibia)
- M. Garassino (Milan, Italy)
Speakers
- G. Galli (Milan, Italy)